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Abstract
Ageing is the main risk factor for human neurological disorders. Among the diverse molecular pathways that
govern ageing, epigenetics can guide age-associated decline in part by regulating gene expression and also
through the modulation of genomic instability and high-order chromatin architecture. Epigenetic mechanisms
are involved in the regulation of neural differentiation as well as in functional processes related to memory
consolidation, learning or cognition during healthy lifespan. On the other side of the coin, many neurodegenerative
diseases are associated with epigenetic dysregulation. The reversible nature of epigenetic factors and, especially, their
role as mediators between the genome and the environment make them exciting candidates as therapeutic targets.
Rather than providing a broad description of the pathways epigenetically deregulated in human neurological
disorders, in this review, we have focused on the potential use of epigenetic enzymes as druggable targets
to ameliorate neural decline during normal ageing and especially in neurological disorders. We will firstly
discuss recent progress that supports a key role of epigenetic regulation during healthy ageing with an
emphasis on the role of epigenetic regulation in adult neurogenesis. Then, we will focus on epigenetic alterations
associated with ageing-related human disorders of the central nervous system. We will discuss examples in the
context of psychiatric disorders, including schizophrenia and posttraumatic stress disorders, and also dementia
or Alzheimer’s disease as the most frequent neurodegenerative disease. Finally, methodological limitations and
future perspectives are discussed.
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Background
Ageing, defined as the progressive functional decline of
organisms at molecular, cellular and physiological level,
is the main risk factor for major human diseases such as
cancer, cardiovascular diseases or neurological disorders
[1]. As a part of natural ageing, the human brain and
nervous system go through natural changes that result
in neuronal death and decline of memory, cognitive and
coordination processes, among other functional im-
pairments. The effects of ageing on the central ner-
vous system are widespread, have multiple aetiologies
and have different clinical manifestations depending
on the person.
We must highlight that age-associated decline is part
of the natural lifespan; however, this loss of neural func-
tion can also be associated with pathogenic conditions
in a broad range of human disorders, including neuro-
developmental diseases (e.g. Rett syndrome), neurode-
generative disorders (dementia, Alzheimer’s disease,
Parkinson’s disease, amyotrophic lateral sclerosis, etc.) or
changes in behaviour leading to psychiatric diseases.
Most of these complex disorders are the result of alte-
rations in multiple molecular pathways together with the
interaction of environmental factors.
It is clear that accumulating evidence of how these
ageing-associated processes occur at molecular level will
provide promising “druggable” targets for therapy in
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ageing-related disorders. In this way, much attention is
paid to the molecular basis of ageing using many experi-
mental cellular contexts, such as telomere shortening,
DNA damage, loss of proteostasis and degeneration of
cell or organ structures [1]. Nowadays, it is also widely
accepted that changes in epigenetic modifications are a
phenomenon associated with ageing throughout the
control of gene expression and genomic instability [2, 3].
The dynamic and reversible nature of epigenetic alter-
ations makes epigenetic mechanisms optimal targets for
the development of novel treatment strategies in neuro-
logical disorders, a strategy that is currently used in the
clinical management of other human complex disorders
such as cancer [4].
In this review, we will summarize our current
knowledge about the involvement of epigenetic factors
in normal ageing (ageing-associated epigenome) and
those environmental factors influencing the epigenetic
landscape of an organism and that can be more easily
modified with lifestyle (e.g. diet, stress or smoking).
Since the use of agents and manipulations that boost
neurogenesis is an important strategy to improve
neurological function in human disorders with neural
decline, we will also summarize the current uses of
epigenetic-based treatments to improve adult neuro-
genesis. Additionally, we examine the preclinical stu-
dies about the use of pharmacological treatments to
reverse the epigenetic signature and ameliorate neural
dysfunction in human disorders, including common
psychiatric disorders (schizophrenia and posttraumatic
stress disorder), dementia and the most well-known
neurological disorder, Alzheimer’s disease. In recent
years, a lot of attention has been paid to the role of
non-coding RNAs (ncRNAs) in the neural differenti-
ation processes but also in the ethiopathology of
neurological disorders [5]. However, due to current
lack of ncRNA-based therapeutic strategies, we will
focus on evidence accumulated with treatments tar-
geting DNA methylation (and DNA demethylation)
and histone modifications. In most cases, especially in
psychiatric disorders, knowledge is still in its infancy
and many questions about the epigenetic basis under-
lying the disease are yet to be addressed. Neurode-
generative diseases are a complex heterogeneous
group of diseases, and the comprehensive understan-
ding of the mechanisms involved in their initiation
and progress should overpass some limitations in the
research strategies. Some improvements are still
needed, including increased sample size of the co-
horts, more appropriate animal models for the dis-
eases, multicentric validations or multivariable
analysis. Elucidating the epigenetic signatures of brain
diseases is imperative to developing and applying
epigenetics-driven therapeutic approaches.
Main text
Age-related epigenetics
Studies of the epigenome have outlined a chromatin sig-
nature during human normal ageing. It is described that
there is a general loss of histones [6] together with a
massive alteration in the histone modification patterns.
The global trends of the ageing- associated histone code
are a loss of repressive marks and a gain of activating
transcriptional marks, both actions resulting in gain and
loss of heterochromatin regions. As examples, redistri-
bution of the active histone mark H3K4me3 over tissue-
specific genes [7] or gain of H4K16ac and H3K56ac [8]
are hallmarks of ageing. As a consequence of the histone
switch, widespread transcriptional deregulation occurs
that includes global amplification of canonical tran-
scripts [2]. Additionally, there are global and local
changes of the methylome during mammalian ageing
[9, 10]. Decreased CpG methylation was found in ad-
vanced aged blood samples, mainly affecting methy-
lation spots into enhancers. In contrast, gain of
methylation was also observed at specific loci at CpG
islands [10], and interestingly in loci near tissue-
specific genes, genes coding for transcription factors
or genes associated with differentiation and develop-
ment [2]. An important consideration for the role of
CpG methylation in ageing is its tissue specificity,
since methylation loci can vary from one cell type to
another. In spite of potential divergences among tis-
sues should be considered, a slow and gradual loss of
genome-wide methylation (global hypomethylation)
together with gain of methylation at specific loci (spe-
cific hypermethylation) during ageing was also re-
ported in brain human tissues [11]. In summary, the
altered pattern of CpG methylation during one’s life-
span is congruent with the changes in histone modifi-
cations marks at specific transcriptional networks. It
remains to be elucidated what the roles of these spe-
cific genes are in the ageing process.
The relation between the effect of genetic variation
and epigenetics should also be considered. The genetics
underlying longevity have been widely explored [12, 13],
but non-genetic contribution can be a confounding fac-
tor in these studies. Monozygotic twins are exceptional
models for assessing the epigenetic effects of ageing on
identical genomes [14, 15]. These studies showed that
the epigenetic discordance between twins increased with
ageing and support the idea that epigenetic drift is over-
come by environmental factors during lifespan. Finally,
it is important to consider that at present, it is unclear
whether changes in epigenetic marks altered the expres-
sion of genes associated with ageing or whether the dis-
turbance of molecular pathways during ageing results in
epigenetic changes at higher scales in the genome. In
other words, it is still unknown if epigenetic changes are
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drivers or just consequence of the ageing process. Re-
cent technological advances provide useful tools for ad-
dressing these challenges, such as the use of CRISPR/
dCas9 for enzyme targeting. In particular, epigenetic
editing for rewriting the epigenome at specific loci will
greatly contribute to the deciphering of the causative
versus correlative changes in ageing [16].
Epigenetic as a bridge between environmental signals
and genome response during early life and ageing
Internal and external environmental factors that are
well-known contributors of ageing can be integrated into
genome response by means of epigenetic responses
(Fig. 1). Alterations in epigenetic modifications can be
associated with caloric restriction, lower basal metabolic
rate or stress, among others [17]. An increasing number
of studies on the influence of the environment during in
utero and in early stages of development have provided
evidence of how external stimuli during stages of early
life, such as exposure to toxins or nutritional deficien-
cies, govern the extent of disease vulnerability [18]. It
has been proposed that environmental factors may inter-
act with specific loci thereby modifying their expression
through epigenetic mechanisms and increasing disease
susceptibility in later life [19]. The effect of fetal
nutrition, which depends on nourishment provided by
the maternal system, has been widely described both in
animal and human models [19, 20], and a positive rela-
tion between maternal diet and neurodegeneration has
been supported in some human studies. The offspring of
women exposed to the Dutch famine in 1944–1945 had
significantly increased risk of several disorders, including
schizophrenia [21, 22]. Although several components of
the diet can mediate this effect, an association between
vitamin B12 and folic acid supplementation in the
mother’s diet during pregnancy and defects on the mye-
lination in the nervous system of offspring has been de-
scribed [23]. In a similar manner, the negative effect of
fetal exposure to factors such as tobacco, alcohol con-
sumption, stress or infections had also been investigated
in the context of risk to neurological disorders in the
offspring [24–26]. How epigenetics modulate changes in
brain development and functions even across genera-
tions (the named “transgenerational inheritance”) will be
the subject of future research in the field and surely will
contribute to improve strategies supporting healthy
development.
It must be considered that embryonic development is
the most susceptible period due to the high number of
cell replication events and epigenetic drifts that take
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Fig. 1 Epigenetic therapy in neuropsychiatric disorders. A combination of external and internal factors can induce epigenetic changes in the
normal healthy brain during ageing but also under pathological conditions, including neurodegenerative disorders or psychiatric diseases.
Epigenetic therapy, such as pharmacological treatment with DNA-demethylating drugs or HDAC inhibitors, can reverse the distorted epigenetic
modifications and induce specific gene expression programs. Two main strategies can be achieved: first, the use of epigenetic drugs can induce adult
neurogenesis by enhancing cellular reprogramming from neural precursor cells and, second, changes in epigenetic modifications can reverse gene
expression of genes involved in neuronal dysfunction and relevant for the disease
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place during differentiation [18]. In postnatal develop-
ment, several observations can also support the environ-
ment- epigenome connection. Diet is probably the best
example of external stimuli affecting the epigenome and
the ageing phenotype. Restrictions in nutrient intake
(below the levels of malnutrition) extend lifespan and
delay ageing in many organisms from yeast to humans
[27]. One of the major factors activated under conditions
of caloric restriction is Histone Deacetylase (HDAC)
protein Sirtuin 1 (SIRT1) [3, 28]. The beneficial effects
of activation of SIRT1 are exerted, at least in part, by im-
proving mitochondrial function [29], but also because
SIRT1 expression after caloric restriction results in de-
creased levels of inflammation-associated genes [28].
The activity of the sirtuin family of histone deacetylates
is dependent on the cofactor NAD+ and NAD+ levels
decline with age. Modulation of NAD+ availability, for
example as a result of NAD+ donors in the diet, can re-
sult in altered SIRT1 function [30] and contrasts ageing
effects. High NAD+ levels are also a consequence of an
oxidative metabolic state induced by caloric restriction
[3] and ameliorate ageing. Caloric restriction has been
also associated with 5-methylcytosine contents and
Dnmt3 activity in the hippocampus of mice models of
ageing [31]. Similarly, it has also been shown that high
nutrient intake mimics the CpG methylation profile of
ageing cells in the liver [32].
Life stress has been also associated with health span
and longevity and is a risk factor for late-life neuro-
logical and metabolic disorders [17]. Telomere shorten-
ing has been described in association with adult stress
conditions [33]. In addition, life stressors induce alte-
rations in CpG methylation in early stages of development
in humans, affecting specific genes such as glucocorticoid
stress response-mediators [34, 35]. Glucocorticoids can
exert two complementary actions to decrease CpG methy-
lation. On the one hand, they decrease the expression of
the DNA methyltransferase DNMT1 in neurons [36], and
on the other hand, exposure to glucocorticoids may up-
regulate the expression of DNA demethylases from the
ten-eleven translocation (TET) family [37].
Healthy and non-healthy habits can also ameliorate or
accelerate, respectively, ageing. Little is known about the
underlying molecular mechanisms of the beneficial effect
of exercise during ageing, but a few reports about the
role of epigenetics exist. Decreased levels of the histone
deacetylases HDAC4 and HDAC5 and increased levels
of acetylated H3K36 were detected in human skeletal
muscle in the brain after exercise [38, 39]. On the other
hand, tobacco exposure can alter the CpG methylation
status of genes associated with cellular homeostasis and
development of ageing-associated disorders [40]. Further-
more, decreased H4K16Ac and increased H3K27me3
levels at specific locus have been also described in smokers
[41]. Alcohol inhibition of the methionine synthase path-
way, and consequently the S-adenosylmethionine levels,
may be associated with hypomethylation of LINE se-
quences related to alcohol consumption [42].
Again, causal evidence that can directly link environ-
mental factors and specific chromatin reordering through
epigenetic mechanisms, and in consequence, affect ageing
and health span, is still missing. Further research will open
new avenues of chromatin-based strategies to delay (or
even reverse) ageing and ageing-related diseases by ma-
nipulation of lifestyle conditions.
Epigenetic contributions to neurogenesis induction
during ageing
One of the main end-point manifestations associated
with ageing is loss of neuronal function that leads to im-
pairment of memory and cognition. As aforementioned,
epigenetic alterations contribute to the natural process
of “healthy” ageing; however, the reversible nature of epi-
genetic marks adds extra value to them as potential tar-
gets for ameliorating neurological decline during ageing.
Although still far from clinical use, improving adult
neurogenesis is a promising strategy to treat neurological
disorders (Fig. 1). In the adult vertebrate brain, the for-
mation of new neurons takes place in a specific popu-
lation of cells referred as neural stem progenitor cells
(NSPCs). Neurogenesis is generally not a frequent
process under normal physiological conditions, but it is
described to be induced after brain injury [43]. NSPCs
can be found in local niches of the brain, such as the
subventricular zone (SVZ) of the lateral ventricle or the
subgranular zone (SGZ) of the dentate gyrus (DG) of the
hippocampus [44]. Neurogenesis at SGZ has received a
lot of attention due to its involvement in cognitive func-
tions such as memory consolidation. Granule cells, the
providers of excitatory input to the pyramidal cells of
CA3 region, are the unique type of neuron that is gene-
rated from the NSPCs in the SGZ under physiological
conditions [43]. Although it is still unclear how intrinsic
and extrinsic mechanisms induce adult neurogenesis,
different signals have been identified including presence
of specific cytoplasmatic factors (growth factors, neu-
rotrophins, cytokines and hormones, among others),
transcriptional factor network and epigenetic regula-
tors [44, 45].
In recent years, further evidence has demonstrated the
role of epigenetic factors in the maintenance of neural
stem cell renewal and also in the induction of new ma-
ture neurons. Although the contribution of ncRNAs to
neural differentiation has been reported in different ex-
perimental systems, and especially for microRNAs,
knowledge about their functional relevance is still in its
infancy [46] and their therapeutic potential is largely un-
explored. By contrast, the role of CpG methylation and
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histone modifications in neuronal cell fate and stem cell
self-renewal has been widely explored [47–50]. For ex-
ample, well-known pluripotency genes are epigenetically
inactivated by CpG promoter methylation during adult
neurogenesis from NSPCs [47]. Interestingly, changes in
DNA methylation as a consequence of external stimuli
and promotion of adult neurogenesis have been de-
scribed. Physical exercise can induce neurogenesis, and
during this process, an association with changes in the
promoter methylation of the neurotrophic factor BDNF
[48] were described. Loss of demethylation by active
mechanisms should also be considered, such as the acti-
vation of the GADD45B demethylase in the DG cells
during adult neurogenesis [49] or the transformation of
5-methylcytosine (5-mC) into 5-hydroxymethylcytosine
(5-hmC) by enzymes of the TET family [50]. 5-hmC is
enriched in adult neurons compared to NSPCs of the
SVZ in the mouse developing brain and colocalize with
MeCP2 and with the active chromatin histone modifica-
tion H3K4me2 in mouse neurons [51]. Another mechan-
ism by which CpG methylation results in transcriptional
silence is by binding to methyl-CpG-binding proteins
that recruit several chromatin remodelling proteins. As
an example, it has been described that the Methyl-CpG-
Binding Domain Protein 1 (MBD1) suppresses the ex-
pression of FGF-2 promoting differentiation during adult
neurogenesis in the hippocampus [52]. MECP2 encodes
an epigenetic factor that influences chromatin structure
and considered to act mainly as a transcriptional repres-
sor [53]. Furthermore, recent studies using induced
pluripotent stem cells derived from Rett patients (a dis-
order causes generally by point mutations on the
MECP2 gene) demonstrated the role of the MeCP2 pro-
tein in neuronal maturation [54]. In addition to DNA
methylation, histone modifiers serve as important regu-
lators in neuronal development. Mll1 (mixed-lineage
leukaemia 1) is a histone methyltransferase (HMT) that
is required for neuronal differentiation in the adult SVZ
and its effect can be exerted by regulating the expression
of DLX2 by increasing H3K27 methylation [55]. Histone
acetylation-related enzymes, such as HDAC2, also im-
pact the maturation and survival of adult neurons in the
SVZ region [56].
The idea of effective stimulation of neuronal produc-
tion by using epidrugs is highly attractive, and although
in its infancy, it is supported by several lines of evidence
(Table 1). Interestingly, pharmacological inhibition of
HDAC activity alters neuronal differentiation. It has
been reported that treatments with trichostatin A (TSA)
or valproic acid (VPA) induced neuronal differentiation
in adult progenitor cells [46, 57]. VPA treatment also
improved the differentiation of sympathoadrenal pro-
genitor cells into catecholaminergic neurons [58]. Epi-
genetic drugs targeting histone methylation are less
extensively addressed. Pre-administration of Bix-01294,
a G9a/GLP inhibitor, has a neuroprotective effect in a
mouse model of neurodegeneration induced by ethanol
and prevents deficits in long-term potentiation, memory
and social recognition behaviour [59]. The underlying
molecular mechanisms are still unclear although reacti-
vation of specific genes involved in cell fate after epidrug
treatments has been identified. For instance, TSA treat-
ment of the PC12 cell line results in increased acety-
lation of Lys14 on histone H3 and upregulation of the
expression of nur77 gene [60]. A neuroprotective effect
of HDAC inhibitor (HDACi) treatment mediated by in-
flammation prevention has been also suggested [61]. It
must be highlighted that multitargeting is also possible
after treatment with epigenetic-based drugs due to the
lack of isoform selectivity and also due to the off-target
effects affecting non-histone proteins. As an example,
treatment with the HDACi AR-42 restores the abnor-
malities in histone 4 acetylation observed in an in vitro
model of Kabuki syndrome (with mutations in the
KMT2D histone methyltransferase) and also alters
methylation at H3K4 [62]. Pharmacological manipula-
tion of chromatin complexes is also an alternative. The
histone-interacting BET bromodomain proteins are
downregulated during neurogenesis from NPCs, and the
use of a bromodomain selective inhibitor (JQ-1) results
in an increase in neuronal differentiation [63].
Therapeutic epigenetic-driven approaches to treat
psychiatric disorders
Epigenetic disequilibria could influence neurodevelop-
ment and brain function at the level of neural circuits
and behavioural outcome and be the trigger point of se-
veral psychiatric disorders [64–66] (Table 2). It is well
known that genetic and environmental factors contribute
to the underlying cause of schizophrenia (SZ) [66–73].
Recently, it was shown that the mammalian brain suffers
a global epigenomic reconfiguration during fetal to
young adult development which could influence SZ on-
set specifically before the age of 20 [11]. Epigenetic pro-
cesses can be developmentally regulated, altered by
drugs and environmental factors, and be tissue-specific
[65, 66, 71, 74] and provide links between clinical mani-
festations of the psychiatric phenotype and lifestyle. For
example, inhalation of nicotine by tobacco smoking (a
confounding factor), regularly practised by SZ patients,
could work as a self-medication. It is proposed to cor-
rect a cholinergic (nicotinic) neurotransmission deficit in
those patients via epigenetic actions on GABAergic neu-
rons [71, 75].
It is also remarkable that pathways relevant for actual
therapeutic management of SZ are regulated by epige-
netic mechanisms. Clinically, the main antipsychotic
treatments target the dopaminergic, serotoninergic and
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monoaminergic receptor systems that exert therapeutic
effects in SZ patients [67]. The aetiology of SZ and life-
time antipsychotic use has been associated with DNA
methylation changes in MEK1 gene promoter in the
frontal cortex of the post-mortem brain. Around 30% of
people with SZ have treatment-resistant SZ, and in this
case, clozapine is the only effective treatment [73]. In
mice, GADD45b mRNA is increased by clozapine [76],
but not haloperidol, via stimulation of H3K9 acetylation
[77]. Clozapine may exert its therapeutic actions by act-
ing on GABAergic and glutamatergic gene promoters
[76, 78, 79], in part targeting DNA methylation via
GADD45b, as well as histone methylation and chroma-
tin relaxation [6].
Research during the last two decades suggested that ab-
normal RELN, DNMT1 and glutamic acid decarboxylase
67 (GAD67) neuronal expression are a feature observed in
animal and human brains of SZ patients [71, 80]. Human
post-mortem studies show that RELN is downregulated in
GABAergic neurons of psychotic patients due to promoter
hypermethylation of RELN gene that is associated with an
increase in DNMT1 and DNMT3a which is consistent
with the “epigenetic GABAergic theory of major psychosis”
[71, 80]. Interestingly, early life stress can impact the
methylation levels of selected promoters; accordingly, be-
havioural programming is possible and potentially rever-
sible, at least, in animal models [81]. In a mouse model of
prenatal restraint stress that induces epigenetic remodelling
in offspring, clozapine but not haloperidol reduces the in-
creased DNMT1 and TET1 levels in frontal cortex of adult
prenatal restraint stress mice and also reduces DNMT1
binding to RELN, GAD67 and BDNF promoters [82].
In SZ, HDACis also have a lot of potential as pharmaco-
logical treatments. In this context, histone H3 phosphory-
lation is increased in peripheral blood mononuclear cells
when compared to healthy controls [83]. It is known that
some HDACis facilitate DNA demethylation [84]. More-
over, combinations of various antipsychotics (e.g. cloza-
pine, olanzapine, quetiapine) and valproic acid (VPA), a
HDACi that reduces MeCP2 binding to RELN and
GAD67 promoters [85], might prove beneficial in the
treatment of SZ based on results from animal and clinical
studies [73].
Lastly, disequilibria in microglia and mitochondrial
function must also be taken into consideration when dis-
cussing SZ. Microglia is important for immune defence
in the central nervous system, and the HDACi butyrate
influences microglial function and has potential thera-
peutic functions in SZ [86]. It is known that butyrate
among other functions in the CNS reinforces memory
function [87] and synaptic plasticity [64, 88]. Mitochon-
drial dysfunction and cellular energy dysfunction are also
associated with SZ. In this context, the butyrate and se-
veral carnitinoids could have potential as therapeutic
agents to treat SZ and other brain disorders [88].
Posttraumatic stress disorder (PTSD) can develop as a
result of a terrifying and traumatic event that can have
short-term or long-lasting effects on neuronal function,
brain plasticity and behavioural adaptations to psycho-
social stressors [89, 90]. Excessive fear and anxiety are
some of the main hallmarks of PTSD where extinction
training leads to a gradual reduction of fear called “fear
extinction” in animals and “exposure-based therapy” in
humans. This extinction mechanism and its molecular
mechanisms are well conserved across species [90–92].
Considerable progress has recently been made in the
preclinical development of cognitive enhancers (e.g. D-
cycloserine, yohimbine and glucocorticoids) that poten-
tiate fear extinction. As a result, several targets had been
identified, including diverse neurotransmitter systems
but also proteins from the IGF2, BDNF and FGF2 path-
way or epigenetic modifications and their downstream
signalling pathways [90, 91]. The PTSD phenotype is
complex and, as many other brain diseases, emerges
from interactions between multiple genetic and epige-
netic factors [89, 90]. We will focus on the most-well
studied epigenetic modifications in fear extinction, DNA
methylation and acetylation of histone proteins. However,
Table 1 Epigenetic-based treatments associated with manipulation of neurogenesis in mammals
Experimental system Organism Epigenetic drug Functional effect Ref.
Neural progenitor cells Rat VPA Promotion of neuronal fate, inhibition of glial fate [46]
Adrenomedullary sympathoadrenal progenitors Bovine VPA Promotion of catecholaminergic neuronal differentiation [58]
Brain neuroblastoma Mouse TSA Induction of neurite extension [201]
Cerebella granule neurons Rat TSA Promotion of neuronal outgrowth [202]
Adrenal medulla progenitors Rat TSA, VPA Induction of neurite outgrowth [60]
Neural progenitor cells Mouse JQ-1 Promotion of neurogenesis, inhibition of gliogenesis [63]
Neural progenitor cells Mouse SAHA, TSA Reduction in neurogenesis in the ganglionic eminences,
increase in neurogenesis in the cortex
[203]
Primary glial cultures and glioblastoma cells Human VPA Alteration of glial cell morphology [204]
Neural stem cells Rat 5-AZA Reduction of migrated neurons and differentiation [205]
Representative examples of studies are included. 5-AZA 5-aza-cytidine, SAHA suberoylanilide hydroxamic acid, TSA trichostatin A, VPA valproic acid
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Table 2 Epigenetic dysregulation in schizophrenia, PTSD (post-traumatic stress disorders) and Alzheimer’s disease
Disorder Gene Molecular effect Specie Method References
Schizophrenia
EPHA4, PKNOX1, ESR1,
among others
DNA methylation,
hsa-miR-219a-5p
Human Gene set enrichment analysis [206]
NUBP1, PRKCE, HLA-
DQA1, HLA-B, FRK,
IL12RB1, among others
DNA methylation Human DNA methylation array [74]
FAM63B, among others DNA methylation Human Methylome-wide association study, targeted
pyrosequencing of bisulfite-converted DNA
[207]
GAD67 DNA methylation, H3
acetylation
Mouse MeDIP, ChIP, qPCR, Western Blotting [75, 77, 85]
REELIN DNA methylation, H3
acetylation
Mouse, Human MeDIP, ChIP, qPCR, Western Blotting, Gel Shift
Binding Assays, Methylome-wide association
study, targeted pyrosequencing of
bisulfite-converted DNA
[77, 85, 207,
208]
BDNF DNA methylation, H3
acetylation
Mouse, Human MeDIP, ChIP, qPCR, Microarray-based DNA
methylation profiling
[76, 209]
mGlu2 DNA methylation, H3
acetylation
Mouse Bisulfite sequencing, ChIP, qPCR [210]
HLA genes, among
others
Histone acetylation Mouse Microarray studies, qRT-PCR, Western Blotting [114]
COMT DNA methylation Human Bisulfite, DNA sequencing, Methylated Specific
PCR and bisulfite sequencing, qRT-PCR
[211, 212]
S-COMT DNA methylation Human Pyrosequencing [213]
FOSP2 DNA methylation Human Bisulfite DNA sequencing [214]
HTR2A DNA methylation Human Bisulfite DNA sequencing [215]
SOX10 DNA methylation Human Bisulfite DNA sequencing [216]
5HTR1A DNA methylation Human High-resolution melt assay [217]
MAOA DNA methylation Human Methylated Specific PCR [218]
MEK1 DNA methylation Human Microarray-based DNA methylation profiling [219]
CAMKIIγ miR-129 Mouse miRNA array profiling, miRNA specific RT-PCR [220]
PTSD
BDNF H4 acetylation Mouse, Rat Western Blotting, ChIP, qPCR [221, 222]
FKBP5 DNA methylation/
hydroxymethylation
Mouse Bisulfite sequencing, Pyrosequencing [34, 223]
HDAC1, cFos H3 acetylation and
methylation
Mouse ChIP, qPCR [224]
NR2B H3 and H4 acetylation Rat Western Blotting, ChIP, RT-PCR [225]
CBP, p300, PCAF H2B and H4 acetylation Rat Western Blotting, ChIP, PCR [226]
Calcineurin (CaN) DNA methylation Rat Bisulfite sequencing [227]
PP1 DNA methylation Rat DNA methylation assay [228]
REELIN DNA demethylation Rat DNA methylation assay [228]
IGF2, cFOS, ARC H3 acetylation Mouse ChIP, qPCR [229]
TLR1, IL8, CNTN2, among
others
DNA methylation Human DNA methylation array [230, 231]
MAN2C1 DNA methylation Human DNA methylation array [232]
IGF2, H19, IL8, IL16, IL18 DNA methylation Human Pyrosequencing [233]
COMT DNA methylation Human DNA methylation array [234]
ADCYAP1R1 DNA methylation Human DNA methylation array [235]
NR3C1 DNA methylation Human Pyrosequencing and clonal sequencing [236–238]
SLC6A3 DNA methylation Human DNA methylation array [239]
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Table 2 Epigenetic dysregulation in schizophrenia, PTSD (post-traumatic stress disorders) and Alzheimer’s disease (Continued)
SLC6A4 DNA methylation Human DNA methylation array [240]
APC5, TPR, CLEC9A,
ANXA2, TLR8
DNA methylation Human DNA methylation array [241]
FKBP5 miR-511 Mouse qPCR [242]
Alzheimer’s disease
APP DNA methylation Human MSRE-SB, pyrosequencing [125–127]
BACE1 DNA methylation Cell lines HPLC [129]
PSEN1 DNA methylation Cell lines HPLC [129]
Neprylisin DNA methylation Cell lines MS-PCR [131]
DUSP22 DNA methylation Human BS-array, pyrosequencing [117]
DUSP22 DNA
hydroxymethylation
Human WG 5-hmC-enriched seq [117]
SORBS3 DNA methylation Human BS-array, pyrosequencing, MS-PCR [116, 132]
NF-kB DNA methylation Human and Cell
lines
Specific Methylation Assay [133, 134]
COX2 DNA methylation Human and Cell
lines
Specific Methylation Assay [134]
BDNF DNA methylation Human MSRE-PCR [133]
CREB DNA methylation Human MSRE-PCR [133]
TBXA2R DNA methylation Human BS-array, pyrosequencing, MS-PCR [116]
ANK1 DNA methylation Human WGBS, BS-array, pyrosequencing [121, 122]
BACE1 H3 acetylation Human FAIRE/ChIP [130]
Neprylisin H4 acetylation Cell lines ChIP [144]
miR-9 downregulation Human PCR [179]
miR-26a upregulation Human PCR [161]
miR-29a/b-1 downregulation Human miRNA microarray [164]
miR-29c downregulation Mouse RT-PCR [164, 168]
miR-34c downregulation Human RNA sequencing [178]
miR-101 downregulation Cell lines PCR [158]
miR-106b downregulation Human miRNA microarray, Northern blot [157]
miR-107 downregulation Human miRNA microarray [163]
miR-124 downregulation Human RT-PCR [160]
miR-125 upregulation Human Northern blot [161, 174, 183]
miR-132 downregulation Human Northern blot [161, 174, 183]
miR-137 downregulation Human PCR [162]
miR-153 downregulation Human PCR [158]
miR-181c downregulation Human PCR [161, 162, 179]
miR-132 downregulation Human Northern blot [174]
miiR-219 downregulation Human RNA sequencing [170]
miR-339-5p downregulation Human and Cell
lines
RT-PCR [167]
BACE1-AS upregulation Human and Cell
lines
RT-PCR [169]
lnc-17A upregulation Human RT-PCR [184]
DNA methylation, histone alterations and microRNA expression is summarized. BS-array bisulfite-modified DNA based arrays, ChIP chromatin
immunoprecipitation, FAIRE formaldehyde-assisted isolation of regulatory elements, HPLC high-performance liquid chromatography, MeDIP
methylated DNA immunoprecipitation, MS-PCR methylation specific PCR, MSRE-PCR methylation-sensitive restriction enzyme-PCR, qPCR
quantitative real-time PCR, WG 5-hmC-enriched seq whole-genome sequencing analysis of 5-hydroxymethylcytosine-enriched sequences,
WGBS whole-genome bisulphite sequencing
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the importance of ncRNAs in post-transcriptional re-
gulation of gene expression in PTSD is well established
[89, 93, 94]. It can be mentioned as an example the role of
miR-138b that inhibits the original fear memory and
downregulates plasticity-related genes (e.g. creb1 and sp1)
in the infralimbic prefrontal cortex of mice [95]. Based on
current literature, successful fear extinction is mediated by
epigenetic mechanisms, which include enhancement of
HAT activity, reduction of HDAC activity (e.g. HDAC2),
DNA methylation and DNA demethylation by TET pro-
teins [89, 90]. There are several animal and human studies
supporting the role of DNA methylation in PTSD [89]. In
mice, for example, DNA methylation is increased in
BDNF exon IV in females resistant to fear extinction,
which leads to a decrease in BDNF expression in the pre-
frontal cortex [96]. Interestingly, it has been demonstrated
in mice that IGF2/IGFBP7 signalling regulates fear extinc-
tion via an upregulation of IGF2 and downregulation of
IGFBP7, which promotes survival of 17–19-day-old new-
born hippocampal neurons [97]. Both IGF2 and IGFBP7
genes are regulated via DNA methylation and other epi-
genetic mechanisms [91, 98]. This signalling pathway
might have potential as therapeutic target for PTSD, al-
though this possibility will need to be studied further.
In humans, several genes associated with stress response
(e.g. NR3C1, FKBP5), neurotransmitter activity (e.g.
SLC6A4), immune regulation (e.g. IGF2, H19, IL8, IL16,
IL18) and repetitive genomic elements (e.g. LINE-1, Alu)
were studied in peripheral blood using either a candidate
genetic locus or a genome-wide approach. It was found that
their methylation levels are altered in PTSD patients [89].
The TET family of methylcytosine dioxygenases enzymes
(TET1, TET2 and TET3) undergoes DNA demethylation
(i.e. reverses DNA methylation), which seems to also play
an important role during fear extinction [99]. One recent
study demonstrates that gene knockdown of TET1 impairs
extinction [100]. Furthermore, another study shows that 5-
hmC and TET3 occupancy undergo genome-wide redistri-
bution on extinction-related genes and that Gephyrin
mRNA expression is increased in the infralimbic prefrontal
cortex [101]. These preclinical findings have made TET en-
zymes and DNA demethylation promising therapeutic tar-
gets to potentiate fear extinction; however, compounds that
target the TET enzymes and subsequently DNA demethyla-
tion are not yet available.
SPV106, a HAT p300/CBP-associated factor (PCAF)
activator, facilitates fear extinction and protects against
fear renewal when injected in rodent infralimbic pre-
frontal cortex [102]. On the other hand, if we inhibit
HAT p300 in the infralimbic cortex, strengthen fear ex-
tinction is enhanced [103]. Thus, HAT modulators affect
fear extinction in different ways, and additional work is
required to unravel their mechanisms of action. Alterna-
tively, gene transcription of extinction-relevant genes
that can be enhanced by HDAC inhibitors such as TSA,
sodium butyrate, entinostat (MS-275), vorinostat (SAHA),
VPA and Cl-944 can strengthen fear extinction displaying
better selectivity towards class-I HDACs [89, 90]. In this
context, targeting specific HDAC isoforms could be a use-
ful therapeutic approach to modulating fear extinction
[104]. Moreover, MS-275, SAHA and Cl-944 rescue fear
extinction deficits in various rodent models [89, 90], and
HDAC2 seems to play a crucial function in this rescue
[105]. Bahari-Javan et al. observed in rodents that HDAC1
is required for extinction learning that comprises H3K9
deacetylation followed by H3K9 trimethylation of target
genes [92, 106]. These facilitating effects on fear extinction
are likely due to initiation of various extinction-related
gene transcription programs. For example, SAHA and
VPA increase acetylation in the promoter of GRIND2B
(NMDA receptor subunit 2B) and histone H4 acetylation
in the promoter IV of BDNF; Cl-994 increases histone H3
acetylation in the promoter region of plasticity associated
genes (e.g. IGF2, ARC, C-FOX), and some neurotransmit-
ter systems increase H3 acetylation in the promoter of
certain genes (e.g. BDNF, CAMK2A, CREB) [90, 105].
Epigenetic link between psychiatric disorders and
dementia
Gene expression in the human brain changes with age
[106], and it is known that some psychiatric disorders (e.g.
SZ, PTSD and depression) may trigger or accelerate the
progression of dementia, a neurodegenerative disease [92,
107–109]. Although the specific molecular link has not
been properly established, epigenetic effects on disease phe-
notypes may explain how early life stressors (e.g. a psychi-
atric disorder) can account for the susceptibility of
dementia later in life [11]. For example, in this context,
there is evidence showing that childhood abuse induces dif-
ferential DNA methylation and gene expression patterns in
PTSD patients compared to PTSD patients without child-
hood abuse [110]. IGFBP7, one of the seven IGFBPs identi-
fied in the mammalian genome that is used to transport
and regulate the bioavailability of IGF1 and IGF2, is deregu-
lated in PTSD and dementia via Igfbp7 promoter DNA
methylation in mouse and human brains [91, 98]. In this
context, epigenetic pharmacology emerges as an appealing
alternative to treat multifactorial diseases with deregulation
in multiple signalling pathways in the framework of person-
alized medicine [111].
Epigenetic mechanisms are essential for normal brain
function (i.e. learning and memory processes), and on
the basis of the literature presented in this review, dis-
ruptions of these mechanisms are closely related to the
molecular alterations associated with disorders such as
depression or Alzheimer’s disease. Alzheimer’s disease
(AD) is the most prevalent form of dementia currently
affecting more than 48 million people worldwide with
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devastating consequences for the affected patients, their
relatives and health systems. Its incidence is expected to
double every 20 years (from 74.7 million in 2030 to
131.5 million in 2050, according to the World Alzheimer
Report 2015). Increasing life expectancy calls for the
urgent development of strategies to delay, attenuate or
prevent Alzheimer’s disease, since therapeutic ap-
proaches directed only at the moderate-to-late stages
have been disappointing in clinical trials so far. AD is di-
vided in two subtypes: familial and sporadic cases. Fami-
lial AD (FAD) accounts for only approximately 5% of all
AD cases and is associated with inherited mutations in
the amyloid precursor protein (APP) gene and the prese-
nilin 1 and 2 (PSEN1/2) genes [112]. This subtype is
characterized by presentation of the major hallmarks of
the disease before the age of 55 years (early onset AD
(EOAD)). Sporadic cases of AD usually present a later
age of onset (≥65 years; late onset AD (LOAD)), and the
scientific community has still not associated this subtype
to any genetic mutation. Thus, identification of non-
genetic factors that trigger sporadic forms of the disease
is crucial in terms of prevention, and knowledge of the
underlying etiopathogenic mechanisms will aid the de-
velopment of timely interventions.
Epigenetic deregulation in neurodegenerative disorders:
Alzheimer’s disease as a model
Since recent studies have described that gene–environ-
ment interactions may underlie neuropsychiatric disorders
[113–115], many research efforts have been oriented into
the study of the alterations of the “physiological epige-
nome” associated with AD [116, 117]. Epigenetic mecha-
nisms, such as modifications of DNA-structure or of
associated histones, regulate gene transcription and may
contribute substantially in the interplay of genetic and en-
vironmental factors in the determination of the human
phenotype [118–120]. Alterations of the levels of 5-mC
and 5-hmC and other epigenetic marks during the lifespan
have been associated with the progression of AD. To date,
several groups [121–123] have identified, by epigenome-
wide analysis, several genes regulated by DNA methyla-
tion in human brain AD samples. These studies reflect
that AD, as well as dementias in general, has specific epi-
genetic signatures [124]. In particular, several research
teams have described age-dependent methylation changes
of a number of AD-related genes. APP gene expression is
partially regulated through methylation of the multiple
CpG sites of its promoter, and hypomethylation events
have been described in association with AD in patients
over 70 years of age [125–127]. However, these data could
not be confirmed by another study with bigger cohorts
[128]. Other APP related genes, such as BACE1 (that
codes for an enzyme responsible for the misprocessing of
APP towards toxic Aβ generation), can be regulated via
epigenetic mechanisms and hypomethylation states of that
promoter have been associated with AD [129, 130]. An-
other enzyme associated with Aβ, PSEN1, has also been
shown to have an aberrant methylation status in AD
[129]. Importantly, Aβ itself has been described as an
epigenetic modulator by inducing global DNA hypome-
thylation and specific hypermethylation of Neprilysin, an
enzyme associated with its degradation [131], thus redu-
cing its expression. Therefore, despite still not being well
defined, it seems that the Aβ generation mechanisms are
associated with DNA methylation patterns in a bidirec-
tional manner. Tau protein, the other major pathomolecu-
lar change in AD, has also been shown to be regulated
epigenetically. DUSP22 is a phosphatase with the abi-
lity to dephosphorylate abnormal tau and is downre-
gulated in AD brain samples by hypermethylation of
its promoter [117].
Besides the principal molecules associated with AD, sev-
eral studies have indicated the importance of epigenetic
processes in gene expression regulation that occur in AD.
SORBS3, or Vinexin, encodes for a cell adhesion protein in-
volved in synaptic function, and several groups have found
a hypermethylation of its promoter [116, 132]. This
process normally appears in an age-dependent fashion but
is accelerated in AD. Other genes such as the gene NF-kB
or some regions of the promoter of the gene
Cyclooxygenase-2 (COX-2), both proinflammatory and
associated with inflammatory events in AD, have been re-
ported to be hypomethylated [133, 134]. Hypermethylation
of the promoters of BDNF and cAMP response element-
binding protein (CREB) were found in the frontal cortex of
AD patients [133]. Both proteins are critical for neuronal
survival [135, 136] and have been associated with AD [137].
The importance of the CREB signalling in AD is evident
since other authors have also described alterations in genes
related to this molecular pathway, such as hypermethylation
of Thromboxane A2 Receptor (TBXA2R) [116], a G-
protein receptor regulating CREB [138]. Recent epigenome-
wide association studies (EWAS) identify another gene
called Ankyrin1 (an adaptor protein; ANK1) in hypermethy-
lated state in cortex samples of AD patients [121, 122]. Im-
portantly, the epigenetic state of ANK1 showed a strong
correlation both with early and late stages of the dis-
ease, suggesting its possible validity as a biomarker.
Besides DNA methylation, the role of histone modifica-
tions has been also dissected in AD [5]. However, few stud-
ies have focused on human brain samples. Of all the
histone modifications described so far, lysine acetylation
and lysine methylation are the most common [139]. For ex-
ample, histone acetylation has been described to be reduced
both in the human brain tissue and in AD mouse models
[140, 141]. Importantly, the transcriptional activity of AD
associated genes has been associated with specific histone
marks, such as increased acetylation of H3 at the BACE1
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promoter [130]. This histone mark activates gene transcrip-
tion by relaxing the chromatin structure. One of the pro-
teolytic fragments of APP is the APP C-terminal fragment
(AICD). Several studies have demonstrated the ability of
AICD to recruit, directly or indirectly, the histone acetyl-
transferase TIP60 [142, 143]. The consequences of this
interaction are the repression of Neprilysin expression in
NB7 cells by acetylation of lysines on histone H4 [144].
Also in human samples, other histone marks were found
to be altered. For example, an increase of phosphoryl-
ation of histone H2AX, a histone variant, in the hippo-
campus was found in AD samples [145], as well as
increased global H3 phosphorylation in the frontal cor-
tex [133] and hippocampus [146].
However, most current knowledge on the involvement
of the histone code derives from work done using trans-
genic mouse models. Decreased levels of H4 acetylation
were found in APP/PS1 of the mouse model hippocam-
pus after a learning task [147]. However, deeper analysis
showed an increased H4 acetylation in the CA1 region
of hippocampus together with increased H3 acetylation
and phosphorylation in the prefrontal cortex of another
APP model, the Tg2575 [148]. These data emphasize the
necessity of restricting epigenetic analysis to small brain
areas or even single-cell analysis to completely under-
stand the role of the epigenetic processes in AD. H3 and
H4 acetylation was increased in neuronal cell cultures
from an AD mouse model expressing mutations in APP
and in Tau (3xTg) [149]. Regarding other hallmarks of
AD, hyperacetylation of H3 on the promoter of BACE1
in 3xTg brains [130] leading to increased transcriptional
activity of the gene, as well as on the promoter of
BACE1 and PS1 in N2a cells expressing a mutated form
of APP, has been described [150]. Other modifications
have not been sufficiently studied although experiments
in animal models have explored histone methylation
[151, 152] and ubiquitination [153] involvement in
learning and memory processes, also indicating possible
implications in cognitive impairments.
Although the AD “histone code” remains to be deci-
phered, it is evident that histone alterations play important
roles both by altering histone marks and by changing
the levels of histone modifying enzymes [141, 154] in
dementias and are suitable targets for pharmacological
approaches.
Non-coding RNAs [155] have also been associated with
AD [156]. Several studies have analysed alterations of
miRNA expression in several areas of post-mortem AD
brains, showing a broad spectrum of changes in a multitude
of miRNAs. Some of the most relevant changes occur in
miRNAs targeting mechanisms implicated in APP and/or
its misprocessing towards the amyloidogenic pathway. miR-
106b [157] and -153 [158] are downregulated in AD (tem-
poral cortex and frontal cortex, respectively), and one of its
multiple targets is the mRNA of APP [159]. Other miRNAs
with the ability to regulate APP are miR-101 [158] and
miR-124 [160], and both are described as downregulated in
AD brains. miR-137 and -181c are also downregulated in
AD [161, 162], and their downregulation promotes APP
processing into neurotoxic forms of Ab. Other key mole-
cules of the amyloidogenic cascade like BACE1 are also tar-
geted by several miRNAs. Numerous miRNAs with the
capability of reducing BACE1 levels were found to be
reduced in several areas of AD brains, for example the
miR-29a/b-1 cluster, -29c, -107, -339-5p and -485-5-p
[163–168]. Other ncRNAs also target BACE1, including
the long ncRNA BACE1-AS, by regulating BACE1 RNA
stability. BACE1-AS was described as being in an upregu-
lated state in AD brains samples suggesting its role in incre-
menting BACE1 levels [169]. Tau is also regulated via
miRNAs. miR-219 was found downregulated in the AD hu-
man frontal cortex [170] and is thought to regulate tau
mRNA directly. Another enzyme involved in the aberrant
phosphorylation of tau is Glycogen Synthase Kinase 3β
(GSK3β) that is considered the major modulator of tau
phosphorylation in the brain [132]. Additional studies have
demonstrated that GSK3β is negatively regulated by miR-
26a, a microRNA deregulated in AD [161, 171]. Several
miRNAs impact on several hallmarks of AD simultan-
eously. miR-107 is another miRNA targeting BACE1 [166],
but it is also capable of deregulating cdk5 [172], a kinase re-
lated to tau phosphorylation. In the case of miR-124 and
-137, both target APP metabolism as well as the differen-
tial splicing of tau [161, 173]. miR-9 and miR-132 can also
regulate tau splicing mechanisms [174–176]. Interestingly,
both also have the ability to reduce SIRT1, a sirtuin that
can deacetylate tau [154, 177]. Together with those, miR-
34c and miR-181c can reduce the levels of SIRT1 and all
of them are reduced in AD [162, 178, 179].
Another important alteration in AD is synaptic dismant-
ling and alteration of synaptic transmission [180, 181].
While several miRNAs have been associated with those
mechanisms [182], miR-132 and miR-125b in particular
have been associated with AD. It has been described that
miR-132 is reduced in the hippocampus, cerebellum and
medial frontal gyrus, whereas miR-125 is increased in
these areas [161, 174, 183]. Another ncRNA, the long
non-coding RNA 17A, is elevated in AD brains and regu-
lates GABA transmission [184]. Due to the role of micro-
RNAs in synaptic plasticity [185] and increasing evidence
that dysregulation of miRNAs biogenesis is implicated in
AD, these epigenetic effectors seem critical not only in the
normal gene expression pattern of neurons but also in the
pathophysiology of AD. The complexity of ncRNA func-
tion and their intricate patterns of expression in nervous
system demand further investigation, which may eventu-
ally lead to the discovery of new druggable targets to delay
or prevent AD.
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AD’s pharmacoepigenomics
Overall, it is evident that epigenomic alterations in AD
make suitable targets for therapeutic interventions
(Table 2). However, so far, only histone alterations have
been properly studied in pharmacoepigenomics.
The most common histone modifications (acety-
lation and methylation) are performed by the bal-
anced activity of HATs and HDACs on the one hand
and histone methyltransferases and demethylases
(HDMTs) on the other hand [153, 186]. Due to the
availability of drugs targeting those enzymes, most re-
search performed to describe its role has been per-
formed in mouse models of AD. The induction of
histone acetylation through inhibition of HDACs has
been proposed as a candidate approach to treat AD
based on of several lines of evidence using such
models [187]. One of the first demonstrations of the
role of the potential use of HDACi to treat AD
showed that administration of the unspecific HDACi
sodium butyrate in an AD mice model (CK-p25 mice)
was able to restore cognitive capabilities initially de-
creased in the transgenic mice [188]. An increased
expression of HDAC2 in human AD samples (hippo-
campal area CA1 and entorhinal cortex) and also in
the hippocampal area CA1 and in prefrontal cortex of
the CK-p25 mice and the 5XFAD model has been de-
scribed [141], reinforcing the idea of using HDACi to
treat AD. Administration of another HDAC inhibitor
TSA also improved memory formation in APP/PS1
mice by increasing H4 acetylation in brain [147].
VPA, another inhibitor of HDAC1, was useful in
order to reduce Aβ levels and plaques in the hippo-
campus of an APP model (PDAPP) [189] and also
was able to improve learning capabilities of an AD
mice model. Similar data was obtained in a Tg2576
model treated with the HDAC inhibitor sodium phe-
nylbutyrate, where chronic treatment reduced tau
hyperphosphorylation but could not revert Aβ accu-
mulation [190]. In subsequent studies, the same team
treated younger animals with the same compound
and found decreased Aβ accumulation and reduced
immunoinflammatory events [190] indicating the im-
portance of the disease stage chosen for treatment.
Other drugs, such as SAHA, also improved cognitive
capabilities of APP/PS1delta9 mice [191], and MS-
275, a specific HDAC1 antagonist [192], showed the
same improvement in cognition of APP/PS1 mice to-
gether with a reduction of amyloid plaques in the
hippocampus of treated animals [193]. Although we
still do not completely understand the role of HDAC
inhibition in the brain [194], it seems evident that
selective pharmacological inhibition of some of the
multiple HDAC members is a promising area of re-
search for treating early stages of AD.
Conclusions
The involvement of epigenetic factors as key players in
the ageing process in the brain and in age-related neuro-
degenerative and psychiatric disorders is widely accepted
and provides important insights as to how they can po-
tentially mediate interactions between genetic and envi-
ronmental risk factors. In spite of epigenetic-based
therapy emerging as an appealing alternative approach
to the treatment of neuropsychiatric diseases with de-
regulation in multiple signalling pathways, many unre-
solved questions still hinder the progression of candidate
therapies to clinical trials.
Future translational research approaches to the deve-
lopment of epigenetic therapeutics in neuropsychiatric
diseases must overcome a number of limitations. One of
the first bottlenecks is the heterogeneity in the design of
studies that frequently use different experimental
models, as well as in the particular regions of the brain
analysed and in the variable sensitivity and resolution of
the epigenetic methods employed. Most studies have
been performed with small sample sizes and thus have
low statistical power and have only addressed a few epi-
genetic marks in a few specific tissues. With this level of
heterogeneity, it is very difficult to infer broad conclu-
sions about the implications of epigenetics in neuronal
development and its alterations in neuropsychiatric di-
seases. It is also important to note that studies in living
humans, as opposed to those in in vitro and animal
models, are very scarce. Other limitations regarding the
design of the studies are the phenomenological and di-
chotomous definitions of the disorders, the multiple
clinical manifestations, the inability to control lifestyle
factors and the inability to distinguish chronological cor-
relations between environmental exposure, epigenetic
modifications and disease progression.
In order to address many of the questions mentioned
above and increase the reproducibility of existing epi-
genetic findings, there are several challenges that must
be confronted. Some important ones include the follo-
wing: (1) to carry out larger, longitudinal, multicenter
and prospective studies in order to investigate brain di-
seases and their interactions; (2) to consider tissue and
cell-type specificity by using dissection of brain tissues;
and (3) to include multiple epigenetic marks, genome-
wide studies and integrate the results into specific chro-
matin contexts.
We must also consider the new challenges in epige-
netic research. There is no doubt about the importance
of non-coding RNAs in post-transcriptional regulation
of gene expression in neural differentiation and their de-
regulation in several human disorders, including neuro-
psychiatric diseases [5, 195]. Furthermore, we must add
new layers of complexity such as the epigenetic regu-
lation of RNA (i.e. RNA methylation) [196], three-
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dimensional chromatin structure as a key regulator of
transcription [197] and the epigenetic control of the mito-
chondrial genome that can explain the mitochondrial dys-
function observed in neuropsychiatry diseases [198].
Emerging technologies for epigenetic research can also
improve our knowledge. As one prominent example, the
use of CRIPSR/Cas9 technology and its adaptations to
different models (for example, epigenetic editing) can
demonstrate the causal role of epigenetics in instructing
gene expression [16]. In addition, computational model-
ling can accelerate the search for new epigenetic thera-
peutic approaches to treat neurological disorders, map
them to clinical predictions and further our understan-
ding of complex brain diseases at the individual and
population levels [199]. In light of the latest advances in
induced pluripotent stem cell (iPSC) technology, future
epigenomic brain approaches will involve the study of
specific neuronal populations derived from patient-cells,
allowing a better understanding of the disorder by di-
sease modelling and a faster drug screening/repurposing
in a personalized manner [200].
It is clear that current knowledge of the epigenetic
changes that occur during healthy ageing and patho-
logical conditions in the brain is increasing, but much
research is still required before translating the findings
to clinical practice. This is of particular relevance due to
the numbers of elderly people in third world societies
and the social effects of cognitive impairment. In sum-
mary, we need to overcome important challenges to
identify new epigenetic therapeutic targets and to de-
velop appropriate, randomised and controlled trials with
human subjects.
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